Elevated circulating cathepsin S levels are associated with cognitive decline and neurodegeneration in a cohort of patients reporting memory complaints
Restricted accessResearch articleFirst published online April, 2025
Elevated circulating cathepsin S levels are associated with cognitive decline and neurodegeneration in a cohort of patients reporting memory complaints
As a member of the cysteine protease family, cathepsin S has been implicated in the pathogenesis of various diseases, including Alzheimer's disease (AD), primarily by promoting inflammation.
Objective
Current evidence regarding the role of cathepsin S primarily comes from animal studies. This study aims to explore the clinical relevance of cathepsin S in AD.
Methods
In a cohort of older adults aged 60 or above with memory complaints, we examined baseline plasma levels of cathepsin S and assessed their association with cognitive decline and biomarkers of neurodegeneration during a 36-month follow-up.
Results
Plasma levels of cathepsin S were significantly higher in individuals experiencing longitudinal cognitive decline compared to those without cognitive decline. Furthermore, plasma levels of cathepsin S were associated with declines in Mini-Mental State Examination (MMSE) scores and increases in neurofilament light and pTau181 levels. Higher plasma cathepsin S levels were linked to an increased risk of longitudinal cognitive decline (decrease in MMSE scores of 3 or more), adjusting for age, sex, education, APOE genotype, alcohol consumption, smoking, and comorbidities.
Conclusions
This study provides additional evidence supporting the potential role of cathepsin S in the pathogenesis of AD from a clinical perspective.
KnopmanDSAmievaHPetersenRC, et al.Alzheimer disease. Nat Rev Dis Primers2021; 7: 33.
2.
NicholsESteinmetzJDVollsetSE, et al.Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health2022; 7: e105–e125.
3.
SelkoeDJHardyJ. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med2016; 8: 595–608.
4.
MastersCLSimmsGWeinmanNA, et al.Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc Natl Acad Sci U S A1985; 82: 4245–4249.
5.
Van DyckCHSwansonCJAisenP, et al.Lecanemab in early Alzheimer’s disease. N Engl J Med2023; 388: 9–21.
6.
MintunMALoACDuggan EvansC, et al.Donanemab in early Alzheimer’s disease. N Engl J Med2021; 384: 1691–1704.
7.
SimsJRZimmerJAEvansCD, et al.Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA2023; 330: 512.
8.
DhapolaRHotaSSSarmaP, et al.Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer’s disease. Inflammopharmacology2021; 29: 1669–1681.
9.
LengFEdisonP. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?Nat Rev Neurol2021; 17: 157–172.
10.
LiuY-HZengFWangY-R, et al.Immunity and Alzheimer’s disease: immunological perspectives on the development of novel therapies. Drug Discov Today2013; 18: 1212–1220.
11.
AhmadMHFatimaMMondalAC. Influence of microglia and astrocyte activation in the neuroinflammatory pathogenesis of Alzheimer’s disease: rational insights for the therapeutic approaches. J Clin Neurosci2019; 59: 6–11.
12.
SmythPSasiwachirangkulJWilliamsR, et al.Cathepsin S (CTSS) activity in health and disease - A treasure trove of untapped clinical potential. Mol Aspects Med2022; 88: 101106.
13.
GórskaETylickaMKamińskaJ, et al.20S Constitutive proteasome, 20S immunoproteasome, and cathepsin S are high-sensitivity and independent markers of immunological activity in relapsing-remitting type of multiple sclerosis. J Neurochem2024; 168: 2880–2892.
14.
ScholandKKGallettiJHaapW, et al.Inhibition of cathepsin S in autoimmune CD25KO mouse improves sjögren disease-like lacrimal gland pathology. Invest Ophthalmol Vis Sci2024; 65: 26.
15.
LowryJRKlegerisA. Emerging roles of microglial cathepsins in neurodegenerative disease. Brain Res Bull2018; 139: 144–156.
16.
SeoYKimH-SKangI, et al.Cathepsin S contributes to microglia-mediated olfactory dysfunction through the regulation of Cx3cl1-Cx3cr1 axis in a Niemann-Pick disease type C1 model. Glia2016; 64: 2291–2305.
17.
NüblingGSchuberthMFeldmerK, et al.Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy. Exp Brain Res2017; 235: 2407–2412.
18.
ZhangMXiZSaez-AtienzarS, et al.Combined epigenetic/genetic study identified an ALS age of onset modifier. Acta Neuropathol Commun2021; 9: 75.
19.
WendtWLübbertHStichelCC. Upregulation of cathepsin S in the aging and pathological nervous system of mice. Brain Res2008; 1232: 7–20.
20.
LiuP-PLiuX-HRenM-J, et al.Neuronal cathepsin S increases neuroinflammation and causes cognitive decline via CX3CL1-CX3CR1 axis and JAK2-STAT3 pathway in aging and Alzheimer’s disease. Aging Cell2025; 24: e14393.
21.
Schechter I and ZivECathepsinsS. B and L with aminopeptidases display β-secretase activity associated with the pathogenesis of Alzheimer’s disease. Biol Chem2011; 392: 555–569.
22.
LuYPikeJRChenJ, et al.Changes in Alzheimer disease blood biomarkers and associations with incident all-cause dementia. JAMA2024; 332: 1258–1269.
23.
DienerH-CSaccoRLYusufS, et al.Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol2008; 7: 875–884.
24.
AndersonCTeoKGaoP, et al.Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol2011; 10: 43–53.
25.
ZhangL-YWangD-ZWangJ, et al.Associations of serum antimicrobial peptide LL-37 with longitudinal cognitive decline and neurodegeneration among older adults with memory complaints. J Alzheimers Dis2023; 93: 595–603.
26.
MotoleseFNorataDIaccarinoG, et al.The effect of creatinine level on amyloid-β and tau plasma concentrations in a cohort of Alzheimer’s disease patients without kidney disease. Behav Brain Res2025; 477: 115289.
27.
OsawaYSembaRDFantoniG, et al.Plasma proteomic signature of the risk of developing mobility disability: a 9-year follow-up. Aging Cell2020; 19: e13132.
28.
ChenLLuBYangY, et al.Elevated circulating cathepsin S levels are associated with metabolic syndrome in overweight and obese individuals. Diabetes Metab Res Rev2019; 35: e3117.
29.
RosickáAMTeckentrupVFittipaldiS, et al.Modifiable dementia risk factors associated with objective and subjective cognition. Alzheimers Dement2024; 20: 7437–7452.
30.
ThomasKRBangenKJRotblattLJ, et al.Self- and study partner-reported cognitive decline in older adults without dementia: the role of α-synuclein and amyloid biomarkers in the Alzheimer’s disease neuroimaging initiative. Alzheimers Dement2024; 20: 7777–7787.
31.
LemereCAMungerJSShiGP, et al.The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer’s disease and Down syndrome brain. An immunocytochemical study. Am J Pathol1995; 146: 848–860.
32.
LivelySSchlichterLC. The microglial activation state regulates migration and roles of matrix-dissolving enzymes for invasion. J Neuroinflammation2013; 10: 75.
33.
XuJWangHDingK, et al.Inhibition of cathepsin S produces neuroprotective effects after traumatic brain injury in mice. Mediators Inflamm2013; 2013: 187873.
34.
MielkeMMFrankRDDageJL, et al.Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol2021; 78: 1108–1117.
35.
ChouliarasLThomasAMalpettiM, et al.Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry2022; 93: 651–658.
36.
AshtonNJJanelidzeSMattsson-CarlgrenN, et al.Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring. Nat Med2022; 28: 2555–2562.
37.
JanelidzeSBarthélemyNRSalvadóG, et al.Plasma phosphorylated tau 217 and Aβ42/40 to predict early brain Aβ accumulation in people without cognitive impairment. JAMA Neurol2024; 81: e242619.
